The stock of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) is a huge mover today! About 586,508 shares traded hands. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has declined 2.78% since April 6, 2016 and is downtrending. It has underperformed by 4.73% the S&P500.
The move comes after 8 months negative chart setup for the $32.95 million company. It was reported on Nov, 8 by Barchart.com. We have $2.90 PT which if reached, will make NASDAQ:AEZS worth $4.28 million less.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) Ratings Coverage
Out of 3 analysts covering Aeterna Zentaris Inc. (NASDAQ:AEZS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aeterna Zentaris Inc. has been the topic of 5 analyst reports since August 18, 2015 according to StockzIntelligence Inc. H.C. Wainwright maintained AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) rating on Wednesday, December 2. H.C. Wainwright has “Buy” rating and $12.0 price target. The firm has “Buy” rating given on Monday, November 23 by Maxim Group. Canaccord Genuity upgraded the shares of AEZS in a report on Monday, November 9 to “Buy” rating. H.C. Wainwright maintained AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) on Tuesday, November 24 with “Buy” rating.
According to Zacks Investment Research, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.”
AEZS Company Profile
Aeterna Zentaris Inc., incorporated on October 12, 1990, is a specialty biopharmaceutical firm engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Firm operates through the biopharmaceutical segment. The Firm is engaged in drug development activities and in the promotion of products for others. The Company’s principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Firm focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company’s direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.